Alnylam stock steadies as analysts highlight upside after sharp year-to-date slide
Published on 09/01/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Alnylam Pharmaceuticals Inc. (ISIN US02005N1000) stock is trading in the low $240 range as of August 31, 2026, after a sharp year-to-date decline that has reset expectations around the RNA interference specialist.
Recent coverage on August 31, 2026, points to renewed interest in Alnylam's long-term growth story, with updated valuation work and pipeline data underpinning a wide gap between the current share price and multi-year revenue and earnings forecasts.
For investors, the tension between the near-term drawdown and long-term upside potential is now central to how Alnylam stock is being assessed.
Share price slide and current valuation
According to a detailed stock overview that includes performance metrics through August 31, 2026, Alnylam stock closed at $240.69 on August 31, 2026, up $3.59 or 1.51 percent on that day. This stock profile also notes that the shares were at $397.65 on January 1, 2026, which means they have fallen by 39.5 percent year to date to reach the current level of $240.69.
The same data set highlights that Alnylam's year-to-date return stands at negative 40.51 percent compared with a positive 12.94 percent gain for the S&P 500 index and a positive 19.28 percent one-year return for the benchmark, underscoring how far the company has lagged the broader U.S. market in 2026. This performance comparison frames Alnylam stock as a significant underperformer despite its established commercial RNAi portfolio.
Market data compiled for biotechnology peers show that Alnylam carries a market capitalization of $46 billion as of early September 2026, positioning it as a large-cap biotech name with substantial scale even after the drawdown. This peer table lists Alnylam's market cap explicitly, reinforcing that the valuation reset has occurred from a high base.
Analyst upside case and RNAi cardio data
One of the key elements supporting the upside narrative is fresh analysis of Alnylam's expanded RNA interference cardiovascular data, which has prompted a re-examination of the long-term investment case. A valuation-focused article published September 1, 2026, highlights that certain forward-looking models yield a fair value of $434.72 per share for Alnylam, which implies 81 percent upside relative to the prevailing market price cited in that analysis.
That same discussion notes that some of the most optimistic projections model future annual revenue of $10,900 million and annual earnings of $2,900 million once the RNAi cardiovascular franchise and other pipeline assets are mature, figures that are many times above the company’s current scale.
In addition to valuation work, recent rating actions support a constructive view. One analyst call reported on August 31, 2026, reiterates a Buy rating on Alnylam with a price target of $482.00 per share when the stock was trading at $241, pointing to substantial upside versus that target based on silencing data in RNAi programs.
Another call covered the same day maintains a Buy stance with a $315.00 price target, implying 30 percent upside from a $241 trading level and citing a low price-to-earnings-growth ratio of 0.12 as evidence of attractive valuation relative to growth expectations. This rating summary links the view to mixed trial data but stresses long-term growth drivers.
Taken together, these valuation and rating datapoints show that, while the stock has dropped more than 39 percent since January 1, 2026, at least some forward-looking models and price targets sit well above the current share price, creating a wide dispersion between market pricing and optimistic scenarios.
Recent performance and technical context
On a day-to-day basis, Alnylam’s trading profile in late August 2026 reflects intermittent rebounds within a broader downtrend. The $3.59 gain on August 31, 2026, that took the stock to $240.69 followed prior closes in the mid-$230 range on nearby dates, indicating short-term volatility around key support levels rather than a sustained trend reversal. A cross-listing quotation overview shows recent ADR prices of $241.82, $234.01, $235.93, and $240.14 on sequential late-August 2026 sessions, which aligns with the U.S. market’s late-month range in the low to mid-$230s.
Performance statistics underline how pronounced the decline has been in a longer window. Data assembled in late August 2026 show Alnylam’s one-year return at negative 47.91 percent versus a positive 19.28 percent one-year gain for the S&P 500, reinforcing that the drawdown extends beyond a single quarter and reflects a multi-month de-rating relative to broader equity benchmarks. This return breakdown frames the investment debate less as a short-term trading issue and more as a significant repricing of the stock’s risk and reward.
For investors following technical indicators, the late-August range around $234 to $241 and the substantial negative year-to-date and one-year returns suggest that Alnylam is trading well below prior highs, with any move back toward the $400 level implied by January 1, 2026 data requiring a substantial re-rating.
Business model and key RNAi products
Alnylam’s fundamental story continues to center on RNA interference, a technology that uses small interfering RNA molecules to silence disease-causing genes. Commercially, the company already markets several therapies for rare genetic and cardiometabolic conditions, and pipeline work in cardiovascular RNAi is now an increasingly important part of the thesis.
A recent analysis of expanded cardiovascular RNAi data emphasizes how new clinical results may broaden the use of gene-silencing approaches beyond rare diseases and into larger cardiometabolic populations, potentially supporting multi-billion-dollar revenue ambitions. This pipeline-focused overview points out that the projected $10,900 million in annual revenue and $2,900 million in annual earnings embedded in some forecasts rely heavily on the success of the expanded cardiovascular RNAi program.
Operationally, Alnylam’s business model involves discovering and developing RNAi therapeutics, advancing them through clinical trials, and commercializing approved products either directly or through partners. While the latest quarter’s specific revenue and earnings figures are not detailed in the available day-filtered sources, the multi-year projections cited by valuation models suggest a trajectory from current rare-disease scale toward far larger potential markets if pivotal trials succeed and regulatory approvals follow.
For everyday patients, Alnylam’s marketed RNAi therapies offer targeted gene silencing that can reduce levels of harmful proteins associated with disease, and the company’s focus on both rare and broader cardiometabolic indications reflects an attempt to diversify its revenue base and smooth out the risk associated with any single program.
Stock level and investor takeaway
Alnylam stock’s latest confirmed closing level of $240.69 as of August 31, 2026 on the Nasdaq aligns with a market capitalization of $46 billion, highlighting a company that remains large and strategically important within the biotechnology sector even after substantial share price declines.
For investors, the key question is how to weigh the documented 39.5 percent year-to-date drop and negative 47.91 percent one-year return against forward-looking scenarios that place fair value at $434.72 per share and analyst price targets between $315.00 and $482.00 based on RNAi pipeline progress and long-term earnings potential.
More on Alnylam stock
Further details on Alnylam’s investor relations materials, including earnings presentations and pipeline updates, can be accessed via the company’s official investor site through the broader web, which provides direct company commentary on quarterly performance and strategic priorities.
RNAi therapies anchor product portfolio
At the heart of Alnylam’s commercial offering are RNAi-based therapies that target specific genes involved in disease processes, with approved products focused on rare genetic and cardiometabolic conditions and additional candidates advancing through cardiovascular and other pipelines.
These products aim to deliver durable reductions in disease-causing proteins through gene silencing, and as expanded cardiovascular RNAi data are analyzed, the potential market for Alnylam’s therapies could extend into much larger patient populations than the rare-disease segments that drove its initial commercial success.
Shares consolidate in the low $240s
Alnylam stock most recently closed at $240.69 on August 31, 2026, on the Nasdaq, reflecting a substantial decline from $397.65 at the start of 2026 but a level that some valuation frameworks and analyst targets regard as significantly below fair value based on long-term RNAi growth projections.
Fact box
Company: Alnylam Pharmaceuticals Inc.
ISIN: US02005N1000
Ticker: ALNY
Exchange: Nasdaq
Price (as of August 31, 2026, 4:00 p.m. ET): $240.69 USD
Market cap: $46 billion (as of September 1, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
